ARTICLE | Company News

Celgene licenses drug modifying tech from Amunix

March 5, 2018 8:32 PM UTC

Amunix Operating Inc. (Mountain View, Calif.) licensed its XTEN and ProTIA technologies to Celgene Corp. (NASDAQ:CELG) to discover and develop drugs against unspecified targets. Amunix told BioCentury that the technology is exclusive for Celgene's undisclosed biologics of interest. The companies did not disclose financial terms.

XTEN technology is based on hydrophilic, unstructured, biodegradable proteins and can improve pharmacokinetic properties of therapeutic drugs...